Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Akkerman O, et al. Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3. Int J Infect Dis. 2019. PMID: 30953827 Free article.
Rifampicin and moxifloxacin for tuberculous meningitis.
Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW. Akkerman O, et al. Lancet Infect Dis. 2013 Jul;13(7):568-9. doi: 10.1016/S1473-3099(13)70101-4. Lancet Infect Dis. 2013. PMID: 23809221 No abstract available.
Drug concentration in lung tissue in multidrug-resistant tuberculosis.
Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AH, van der Werf TS, Alffenaar JW. Akkerman OW, et al. Eur Respir J. 2013 Dec;42(6):1750-2. doi: 10.1183/09031936.00047413. Eur Respir J. 2013. PMID: 24293422 Free article. No abstract available.
Raltegravir and rifampicin in patients with HIV and tuberculosis.
Klis S, Daskapan A, Akkerman OW, Alffenaar JW, Stienstra Y. Klis S, et al. Lancet Infect Dis. 2014 Nov;14(11):1046-1047. doi: 10.1016/S1473-3099(14)70977-6. Epub 2014 Oct 19. Lancet Infect Dis. 2014. PMID: 25444405 No abstract available.
Breakpoints and drug exposure are inevitably closely linked.
Alffenaar JW, Akkerman OW, Bolhuis MS, Boeree MJ, de Lange WC, van der Werf TS. Alffenaar JW, et al. Among authors: akkerman ow. Antimicrob Agents Chemother. 2015 Feb;59(2):1384. doi: 10.1128/AAC.04485-14. Antimicrob Agents Chemother. 2015. PMID: 25628393 Free PMC article. No abstract available.
The Never Ending Struggle Against Development of Drug Resistance.
Daskapan A, Stienstra Y, Akkerman OW, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW. Daskapan A, et al. Clin Infect Dis. 2015 Jul 1;61(1):137-8. doi: 10.1093/cid/civ238. Epub 2015 Mar 25. Clin Infect Dis. 2015. PMID: 25810289 No abstract available.
155 results